Bifogade filer
Kurs
0,00%
Likviditet
4,27 MSEK
Kalender
Est. tid* | ||
2026-06-04 | 07:00 | Bokslutskommuniké 2026 |
2026-03-02 | 07:00 | Kvartalsrapport 2026-Q3 |
2025-12-01 | 07:00 | Kvartalsrapport 2026-Q2 |
2025-09-25 | N/A | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2025-09-24 | N/A | Årsstämma |
2025-09-01 | 07:00 | Kvartalsrapport 2026-Q1 |
2025-06-03 | - | Bokslutskommuniké 2025 |
2025-03-03 | - | Kvartalsrapport 2025-Q3 |
2025-01-20 | - | Extra Bolagsstämma 2025 |
2024-12-04 | - | Kvartalsrapport 2025-Q2 |
2024-09-26 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2024-09-25 | - | Årsstämma |
2024-08-29 | - | Kvartalsrapport 2025-Q1 |
2024-05-30 | - | Bokslutskommuniké 2024 |
2024-02-29 | - | Kvartalsrapport 2024-Q3 |
2023-12-04 | - | Kvartalsrapport 2024-Q2 |
2023-10-04 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2023-09-27 | - | Årsstämma |
2023-08-31 | - | Kvartalsrapport 2024-Q1 |
2023-06-08 | - | Bokslutskommuniké 2023 |
2023-03-01 | - | Kvartalsrapport 2023-Q3 |
2022-12-01 | - | Kvartalsrapport 2023-Q2 |
2022-10-03 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2022-09-28 | - | Årsstämma |
2022-08-31 | - | Kvartalsrapport 2023-Q1 |
2022-06-10 | - | Bokslutskommuniké 2022 |
2022-03-02 | - | Kvartalsrapport 2022-Q3 |
2021-12-02 | - | Kvartalsrapport 2022-Q2 |
2021-09-09 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2021-09-02 | - | Kvartalsrapport 2022-Q1 |
2021-05-31 | - | Bokslutskommuniké 2021 |
2021-03-03 | - | Kvartalsrapport 2021-Q3 |
2020-12-02 | - | Kvartalsrapport 2021-Q2 |
2020-09-30 | - | Årsstämma |
2020-09-09 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2020-08-24 | - | Kvartalsrapport 2021-Q1 |
2020-06-08 | - | Bokslutskommuniké 2020 |
2020-04-20 | - | Extra Bolagsstämma 2020 |
2020-03-02 | - | Kvartalsrapport 2020-Q3 |
2019-12-02 | - | Kvartalsrapport 2020-Q2 |
2019-09-30 | - | Årsstämma |
2019-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2019-09-02 | - | Kvartalsrapport 2020-Q1 |
2019-06-10 | - | Bokslutskommuniké 2019 |
2019-03-04 | - | Kvartalsrapport 2019-Q3 |
2018-12-17 | - | Kvartalsrapport 2019-Q2 |
2018-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2018-09-24 | - | Årsstämma |
2018-09-24 | - | Kvartalsrapport 2019-Q1 |
2018-06-25 | - | Bokslutskommuniké 2018 |
2018-03-26 | - | Kvartalsrapport 2018-Q3 |
2017-12-18 | - | Kvartalsrapport 2018-Q2 |
2017-09-25 | - | Årsstämma |
2017-09-25 | - | Kvartalsrapport 2018-Q1 |
2017-06-30 | - | Bokslutskommuniké 2017 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Mölndal, Sweden, August 13, 2025 - Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B), the provider of the OPRA™ Implant System, has announced that it has secured the exclusive title of Legacy Sponsor - the highest level of sponsorship - for the Global Collaborative Congress on Osseointegration (GCCO) annual meeting, held in Charlotte, North Carolina, USA.
This multi-year sponsorship grants Integrum exclusive top-tier recognition for the next three years and underscores the company's long-standing commitment to clinical education, surgical innovation, and international collaboration in the field of osseointegration, known as bone-anchored prosthetics. As a Legacy Sponsor, Integrum will continue to support the global limb loss community by fostering research, advancing outcomes, and engaging cross-disciplinary education.
"We're proud to serve as top sponsor of the GCCO conference. This partnership reflects our shared commitment to facilitating innovation and fostering global collaboration to expand limb loss care. We believe in the power of shared knowledge and scientific evidence to drive long-term impact," said Jeffrey Zanni, President of Integrum Inc.
The GCCO conference brings together leaders in surgical innovation, rehabilitation, prosthetics and clinical research to further the progress being made in the field of bone-anchored prosthetics.
"Integrum's support has been instrumental in driving forward the mission of GCCO-to unite experts across borders to advance limb loss care. Their commitment to innovation and education elevates the quality of our conversations and enables us to continue improving outcomes for amputees worldwide," said Dr. Joseph Hsu, conference chair and orthopedic trauma surgeon.
Integrum's top sponsorship reflects its mission to provide freedom of mobility for every person by driving improved outcomes and greater access to advanced prosthetic solutions. The company remains committed to supporting GCCO's mission and upholding shared objectives within the osseointegration space.
For more information about Integrum or the OPRA™ Implant System, visit https://integrum.se/.
For registration and more information about the GCCO conference visit https://whova.com/portal/registration/1alq-wqaCdERx3smTUms/.
For more information, please contact:
Jeffrey Zanni, President US
Email: Jeff.Zanni@integrum.se
Phone: +1 617-839-1600
Jörgen Svanström, CFO
Mobil: +46 (0) 7073 496 60,
Email: jorgen.svanstrom@integrum.se
Certified Adviser
The Company's Certified Adviser is DNB Carnegie Investment Bank AB.